Journal
CLINICS IN LIVER DISEASE
Volume 15, Issue 3, Pages 627-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2011.05.010
Keywords
Hepatitis C; NS5A; Replication; Inhibitor
Categories
Funding
- Bristol-Myers Squibb Company
Ask authors/readers for more resources
The development and approval of direct-acting antiviral agents looks set to transform the treatment of chronic hepatitis C infection. Among the agents in development are novel compounds that inhibit the function of the NS5A protein: a pleiotropic protein with a complex and essential role in viral replication. Preclinical studies have demonstrated the potency of these agents across a broad range of viral genotypes, and in early phase trials, they rapidly suppressed viral replication when administered as monotherapy or in combination with pegylated interferon-alpha and ribavirin. The discovery and development of NS5A replication complex inhibitors is summarized in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available